Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  US Nuclear Corp.    UCLE

US NUCLEAR CORP.

(UCLE)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

US Nuclear: The Brain Machine Interface Will Change The World

03/02/2020 | 08:31am EST

Chapter 1: Prostheses and Artificial Arms and Legs

LOS ANGELES, CA, March 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – US Nuclear Corp. (OTC: UCLE) recently acquired a 40% stake in Grapheton Inc, and in doing so, joined the future of the brain-machine interface revolution. The first chapter in this new journey is the use of prostheses, or artificial body parts, such as a leg or arm.  

Due to accidents, wars, diabetes, and other causes, over 275 million Americans have lost a limb.  Additionally, many more people still have their limbs, but have lost their ability to use them due to mishaps, spinal injuries, and stroke.   

Cutting edge technology from Grapheton and other pioneers in this field will allow these prostheses to be truly functional and widely available.  Grapheton alone has made several patented advancements, including: long-lasting carbon-based electrodes that do not corrode, self-charging supercapacitors (batteries without toxic chemicals), and two-way multi-modal communication with the brain and motor neurons. US Nuclear has extensive experience in signal processing and will help Grapheton with the ancillary equipment required to process the signal and facilitate communication between the brain and the prosthetic. The age of the wooden leg is over. With today’s technology, we can start replacing passive or cosmetic prostheses with advanced robotic systems.  

The below video and study are produced by UPMC researchers and help demonstrate how Grapheton’s new, soft, and long-lasting ECoG (electrocorticography) probes that record from the surface of the brain and two-way neural communication with the brain and prosthetic would work in a similar fashion.  

https://www.youtube.com/watch?v=L1bO-29FhMU 

The prosthetic market is fueled by a high rate of growth. It was valued at $8.9 billion back in 2018, and with a CAGR of 6%, is projected to reach $15 billion by 2027.   

Safe Harbor Act

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com

CONTACT:
US Nuclear Corp. (OTCBB: UCLE)
Robert I. Goldstein, President, CEO, and Chairman 
Rachel Boulds, Chief Financial Officer
(818) 883 7043
Email: info@usnuclearcorp.com

Primary Logo


© GlobeNewswire 2020
All news about US NUCLEAR CORP.
01/21US Nuclear Corp. Discusses Potential of 2021 Projects with The Stock Day Podc..
NE
01/06US NUCLEAR CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/06US NUCLEAR : 2019 Convertible Debenture Now Fully Converted, Closed, and Flat
AQ
2020US Nuclear Corp. Discusses The Progress of Its MIFTEC Contract and Overhuff T..
NE
2020US Nuclear Corp. Announces Third Quarter 2020 Results
GL
2020US NUCLEAR : Management's Discussion and Analysis of Financial Condition and Res..
AQ
2020US NUCLEAR : and Grapheton Brain Implants to Help Immobilized Patients
AQ
2020US Nuclear and Grapheton Brain Implants to Help Immobilized Patients
GL
2020US NUCLEAR : Secures Its Position at Bioelectronics Startup Grapheton
AQ
2020US Nuclear Secures Its Position at Bioelectronics Startup Grapheton
GL
More news
Financials (USD)
Sales 2019 3,54 M - -
Net income 2019 -3,16 M - -
Net cash 2019 0,10 M - -
P/E ratio 2019 -4,28x
Yield 2019 -
Capitalization 22,9 M 22,9 M -
EV / Sales 2018 2,02x
EV / Sales 2019 3,85x
Nbr of Employees 20
Free-Float 48,4%
Chart US NUCLEAR CORP.
Duration : Period :
US Nuclear Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Robert I. Goldstein Chairman, President & Chief Executive Officer
Richard Landry COO & Director-Investor Relations
Rachel Boulds Chief Financial Officer & Secretary
Michael G. Hastings Director
Dell Williamson Director
Sector and Competitors